Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CordenPharma Increases U.S. Peptide Manufacturing Capacity | Contract Pharma

What are you searching for?

Sign in
Breaking News

CordenPharma Increases U.S. Peptide Manufacturing Capacity

Expansion aims to accommodate a large spike in demand for peptide API’s.

By: Contract Pharma

Contract Pharma Staff

CordenPharma has expanded its peptide manufacturing capacity in CordenPharma Colorado, their GMP API facility in Boulder, Colorado. The expansion was done in order to accommodate for a large spike in demand for peptide API’s and to continue an overall growth strategy.
 
Dr. Matthieu Giraud, director, Global Peptides, Lipids & Carbohydrates Platform, explained, “With the addition of this extra-large 3’000 L SPPS vessel, our assembly-time, capacity and flexibility has been significantly increased, reinforcing CordenPharma Colorado as the current large-scale peptide manufacturing capacity leader. This new asset gives us the ability to manufacture a complex long peptide with a 400 kg output per single batch. Our team in Colorado aims to utilize this new capacity to conduct validation campaigns designed to support customer projects with a global impact.”
 
With approximately 300 employees, CordenPharma Colorado has a long track record in large-scale manufacturing, where all potencies, including picogram levels, can be reached.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics